Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Second addendum to Project A26-11

Report documents

1. Addendum

   Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Second addendum to Project A26-11

   published on

   06.08.2026

   Document type

   PDF document, 291 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/G26-17

   Download file : Addendum (PDF document, 291 kB, DE, not accessible)

Additional information

Project details

Project no.

G26-17

Commission

Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Digestion, metabolism and hormones

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

DOI

https://doi.org/10.60584/G26-17

Connected Projects

1. Dossier assessment

   Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A26-11

   Last updated

   06.08.2026

   Status: Commission completed